Table 4.
Clinical data comparison between patients with and without polypharmacy.
| N | Polypharmacy (all medications) | Polypharmacy (long-term medications only) | ||||
|---|---|---|---|---|---|---|
| Pw/oP | PwP | Statistics | Pw/oP | PwP | Statistics | |
| 133 | 173 | 177 | 129 | |||
| EDSSb | 2.5 | 4.5 | z = −7.991, p < 0.001U | 3.0 | 6.0 | z = −8.062, p < 0.001U |
| Disease coursec | X2(2) = 74.871, p < 0.001Chi | X2(2) = 78.310, p < 0.001Chi | ||||
| CIS/RRMS | 119 (89.5) | 73 (42.2) | 148 (83.6) | 44 (34.1) | ||
| SPMS | 14 (10.5) | 66 (38.2) | 21 (11.9) | 59 (45.7) | ||
| PPMS | 0 (0.0) | 34 (19.7) | 8 (4.5) | 26 (20.2) | ||
| Disease duration (Years)b | 10 | 13 | z = −2.234, p = 0.025U | 9 | 15 | z = −4.592, p < 0.001U |
| Comorbiditiesc | p < 0.001 Fi | p < 0.001 Fi | ||||
| Pw/oSI | 76 (57.1) | 33 (19.1) | 97 (54.8) | 12 (9.3) | ||
| PwSI | 57 (42.9) | 140 (80.9) | 80 (45.2) | 117 (90.7) | ||
| Patient carec | p < 0.001 Fi | p < 0.001 Fi | ||||
| Outpatients | 102 (76.7) | 44 (25.4) | 116 (65.5) | 30 (23.3) | ||
| Inpatients | 31 (23.3) | 129 (74.6) | 61 (34.5) | 99 (76.7) | ||
CIS, clinically isolated syndrome; MS, multiple sclerosis; N, number of patients; PwP, patients with polypharmacy; PwSI, patients with secondary illnesses; Pw/oP, patients without polypharmacy; Pw/oSI, patients without secondary illnesses; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.
bMedian; cnumber of patients (%) ChiChi-square test; FiFisher’s exact test; UMann-Whitney U test.